(R)-7-(三氟甲基)苯并二氢吡喃-4-胺 | 1213657-96-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: (R)-7-(三氟甲基)苯并二氢吡喃-4-胺
• 中文别名: (R)-7-三氟甲基苯并二氢吡喃-4-胺
• 英文名称: (R)-7-(trifluoromethyl)chroman-4-amine
• 英文别名: (4R)-7-(trifluoromethyl)-3,4-dihydro-2H-chromen-4-amine
• CAS: 1213657-96-5
• 化学式: C₁₀H₁₀F₃NO
• 分子量: 217.191
• InChiKey: MMCIPVIZAJIRKM-MRVPVSSYSA-N

物化性质

• 沸点：
  249.7±40.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-7-(三氟甲基)苯并二氢吡喃-4-胺 在 水 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 (R)-1-(1H-indazol-4-yl)-3-(7-(trifluoromethyl)chroman-4-yl)urea
  参考文献：
  名称：

  Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

  摘要：

  Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.056
• 作为产物：
  描述：

  7-(三氟甲基)色满-4-酮 在 吡啶 、 palladium 10% on activated carbon 、 氨 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、413.7 kPa 条件下， 反应 25.0h， 生成 (R)-7-(三氟甲基)苯并二氢吡喃-4-胺
  参考文献：
  名称：

  Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

  摘要：

  Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.056

文献信息

• TRPV1 Antagonists
  申请人：AbbVie Inc.

  公开号：US20130158067A1

  公开（公告）日：2013-06-20

  Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X 1 , L, R x , R y , R z , A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  披露于此的是公式（I）的化合物： 或其药用可接受的盐，其中X 1 ，L，R x ，R y ，R z ，A，m，n，p，q，s，以及位置a和b如说明书所述定义。还披露了包含此类化合物的组合物以及使用此类化合物和组合物治疗状况和失调的方法。
• TRPV1 ANTAGONISTS
  申请人：AbbVie Inc.

  公开号：US20130172334A1

  公开（公告）日：2013-07-04

  Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X 1 , L, R x , R y , G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文公开了公式(I)的化合物：或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如规范中定义。还公开了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。
• US8859584B2
  申请人：——

  公开号：US8859584B2

  公开（公告）日：2014-10-14
• US8969325B2
  申请人：——

  公开号：US8969325B2

  公开（公告）日：2015-03-03
• [EN] TRPV1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV1
  申请人：ABBVIE INC

  公开号：WO2013096223A1

  公开（公告）日：2013-06-27

  Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.